Ming Wears Pom Poms For Dendreon

Ming willingly becomes a cheerleader for Dendreon but adamantly refuses to shave his legs. Ming has reconciled himself to not depending upon a successful interim look if Dendreon isn't privy to a failed p value so as to have grounds for appeal , an option that has been bruted about in the past. A one-percent endpoint is too hard to achieve.So what can Dendreon then do until IMPACT completion in 2010? In 2001, Dendreon received a patent on the gene encoding trp-p8 which is a protein ion channel. An ignorant, unwashed Ming understands that this protein is expressed not only in 100% of prostate cancers, but in 93% of colon cancers, 80% of lung cancers and even 71% of breast cancers. Think about that. If a company wants to create an immunotherapy in any of those indications, they would be well served to license, partner, or otherwise buy access to Dendreon's patented gene that encodes trp-p8 since targeting this protein, targets those cancers. Likewise, this could be germane for small molecule development. So cheerleader Ming, looking quite fetching in his new cheerleader's outfit says, even without immediate Provenge approval, even without Nuevenge development and even with a supine management, trp-p8 alone is likely enough, with our juicy $2.60 per share NOL and tax credit benefit thrown in , to make this a very desirable investment and/or acquisition. So go team.